乳腺癌诊断后对心血管药物遵守的变化:使用法国全国数据进行潜在类轨迹分析
Juliette Artignan1,2, Perrine Capmas3,4,5, Henri Panjo3,4
1Centre for Research in Epidemiology and Population Health (Inserm U1018), Villejuif, France. artignan.juliette@gmail.com.
Breast cancer research and treatment
|January 6, 2026
概括
乳腺癌幸存者在诊断后表现出不同的心血管药物遵从性. 有些人保持坚持,而另一些人急剧下降,特别是在严重的癌症中,突出了针对性干预的必要性.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 公共卫生 公共卫生
背景情况:
- 对于乳腺癌幸存者来说,心血管风险管理至关重要,许多人有先前存在的疾病.
- 诊断后,药物服药通常会减少,但人口平均值掩盖了个体患者的变化.
- 了解合规模式对于改善长期健康结果至关重要.
研究的目的:
- 在乳腺癌诊断的时间内确定心血管药物的独特合规轨迹.
- 根据他们的药物服药模式来描述患者群体.
- 探索与不同合规轨迹相关的因素.
主要方法:
- 利用法国国家健康数据系统对一组被诊断患有乳腺癌的女性 (2016-2020) 进行了分析.
- 包括在诊断前接受至少两种心血管药物类别用于初级预防的妇女.
- 采用基于小组的轨迹建模来分析三年来合规情况.
主要成果:
- 确定了六个不同的合规轨迹,在49.9%的女性中保持稳定的高合规率.
- 观察到显著的子集,其遵守率下降 (急剧下降:9.8%;停止:3.4%;非常低/下降:2.9%).
- 下降的轨迹与更高的转移率和化疗使用相关.
结论:
- 乳腺癌诊断触发了各种各样的心血管药物合规反应.
- 虽然许多幸存者保持坚持,但显著的比例经历了与癌症严重程度相关的下降.
- 诊断后的干预措施对于减轻心血管风险和改善幸存者的结果至关重要.
相关概念视频
Assessment of the Cardiovascular System I: Subjective Data
749
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
749
Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
Therapeutic Drug Monitoring: Affecting Factors
196
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
196
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Heart Failure Drugs: β-Blockers
758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758
Coronary Artery Disease IV: Preventive Measures
580
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
580


